The latest price target for Metagenomi Therapeutics (NASDAQ:MGX) was reported by HC Wainwright & Co. on August 19, 2025. The analyst firm set a price target for $7.00 expecting MGX to rise to within 12 months (a possible 413.95% upside). 5 analyst firms have reported ratings in the last year.

The latest analyst rating for Metagenomi Therapeutics (NASDAQ:MGX) was provided by HC Wainwright & Co., and Metagenomi Therapeutics reiterated their buy rating.

There is no last upgrade for Metagenomi Therapeutics

The last downgrade for Metagenomi Therapeutics Inc happened on May 2, 2024 when JP Morgan changed their price target from $16 to $6 for Metagenomi Therapeutics Inc.

Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Metagenomi Therapeutics, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Metagenomi Therapeutics was filed on August 19, 2025 so you should expect the next rating to be made available sometime around August 19, 2026.

While ratings are subjective and will change, the latest Metagenomi Therapeutics (MGX) rating was a reiterated with a price target of $7.00 to $7.00. The current price Metagenomi Therapeutics (MGX) is trading at is $1.36, which is out of the analyst’s predicted range.